3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
9
Paclitaxel
8
Capecitabine
8
trastuzumab deruxtecan
7
Fulvestrant
7
pertuzumab
5
eribulin
5
Gemcitabine
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
Doxorubicin
4
Carboplatin
4
Ado-Trastuzumab Emtansine
4
sacituzumab govitecan
3
ribociclib
3
Vinorelbine
3
Epirubicin
3
Docetaxel
3
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
neratinib
2
larotrectinib
2
exemestane
2
capivasertib
2
abemaciclib
2
Letrozole
2
Fluorouracil
2
Anastrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
tucatinib
×
Breast
×
Clear all
NCT02614794
2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2
Completed
612 enrolled
30 charts
1 FDA